2.50
Hdl Handle:
http://hdl.handle.net/10541/83217
Title:
Ki-67 index in metastatic prostate cancer.
Authors:
Bryden, A A G; Freemont, Anthony J; Clarke, Noel W ( 0000-0001-7776-8059 ) ; George, Nicholas J
Abstract:
OBJECTIVE: Prostate cancer in bone is generally thought to progress more rapidly than in its primary site, a supposition that is supported by studies of prostate-specific antigen velocity. However, descriptions of proliferative rates in metastases have relied on inferred data from in vitro studies of cell lines derived from metastases. The aim of this study was to determine directly the proliferative rate within bone metastases arising from prostate cancer. PATIENTS AND METHODS: 10 bone biopsies containing metastatic deposits of untreated prostatic cancer were obtained. These were immunohistochemically stained for the Ki-67 protein with the monoclonal antibody MIB-1, using the streptavidin-biotin complex technique. Benign prostatic tissue was used as the control. Using an image analyser, the Ki-67 index (% of cells staining positively) in each specimen was determined. RESULTS: In the 10 specimens the Ki-67 index ranged from 0.15 to 7.82%. Wide overlap was seen between groups of differing tumour differentiation. CONCLUSION: The proliferative rate as determined by the Ki-67 index in bone metastases of prostate cancer is similar to that reported in primary tumours. There does not appear to be a relationship between tumour grade and proliferative index in these specimens.
Affiliation:
Department of Urology, Hope and Christie Hospitals, Manchester, UK. gbryden@hotmail.com
Citation:
Ki-67 index in metastatic prostate cancer. 2001, 40 (6):673-6 Eur. Urol.
Journal:
European Urology
Issue Date:
Dec-2001
URI:
http://hdl.handle.net/10541/83217
PubMed ID:
11805416
Type:
Article
Language:
en
ISSN:
0302-2838
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorBryden, A A G-
dc.contributor.authorFreemont, Anthony J-
dc.contributor.authorClarke, Noel W-
dc.contributor.authorGeorge, Nicholas J-
dc.date.accessioned2009-10-01T14:38:48Z-
dc.date.available2009-10-01T14:38:48Z-
dc.date.issued2001-12-
dc.identifier.citationKi-67 index in metastatic prostate cancer. 2001, 40 (6):673-6 Eur. Urol.en
dc.identifier.issn0302-2838-
dc.identifier.pmid11805416-
dc.identifier.urihttp://hdl.handle.net/10541/83217-
dc.description.abstractOBJECTIVE: Prostate cancer in bone is generally thought to progress more rapidly than in its primary site, a supposition that is supported by studies of prostate-specific antigen velocity. However, descriptions of proliferative rates in metastases have relied on inferred data from in vitro studies of cell lines derived from metastases. The aim of this study was to determine directly the proliferative rate within bone metastases arising from prostate cancer. PATIENTS AND METHODS: 10 bone biopsies containing metastatic deposits of untreated prostatic cancer were obtained. These were immunohistochemically stained for the Ki-67 protein with the monoclonal antibody MIB-1, using the streptavidin-biotin complex technique. Benign prostatic tissue was used as the control. Using an image analyser, the Ki-67 index (% of cells staining positively) in each specimen was determined. RESULTS: In the 10 specimens the Ki-67 index ranged from 0.15 to 7.82%. Wide overlap was seen between groups of differing tumour differentiation. CONCLUSION: The proliferative rate as determined by the Ki-67 index in bone metastases of prostate cancer is similar to that reported in primary tumours. There does not appear to be a relationship between tumour grade and proliferative index in these specimens.en
dc.language.isoenen
dc.subjectBone Canceren
dc.subjectProstatic Canceren
dc.subject.meshAdenocarcinoma-
dc.subject.meshAntibodies, Monoclonal-
dc.subject.meshBone Neoplasms-
dc.subject.meshHumans-
dc.subject.meshImmunohistochemistry-
dc.subject.meshKi-67 Antigen-
dc.subject.meshMale-
dc.subject.meshProstate-Specific Antigen-
dc.subject.meshProstatic Neoplasms-
dc.titleKi-67 index in metastatic prostate cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Urology, Hope and Christie Hospitals, Manchester, UK. gbryden@hotmail.comen
dc.identifier.journalEuropean Urologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.